Erasca Inc. Common Stock (ERAS)
Stock · NASDAQ · Health Care
$13.4as of 10/16/2026
Price chart
Active signals
ERAS Signal Track Record
How signals performed across all stocks →What ERAS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | +1.4% | 55% | September 16, 2026 |
| Bollinger Band BreakdownActive now | 25 | +3.1% | 64% | August 20, 2026 |
| Bollinger Band Breakout | 25 | -7.9% | 36% | August 26, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -1.3% | 43% | October 7, 2026 |
| Any 20-session window (baseline) | -1.2% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ERAS
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 103
- Website
- www.erasca.com/
Fundamentals
- 1-day range
- $14.36$15.25
- Market cap
- $6.25B
- P/E (trailing)
- —
- P/E (forward)
- -23.86
- EPS (trailing)
- $-0.95
- Dividend yield
- —
- Beta
- 0.67
- Avg. volume
- 4.32M
Forecasts
9 analyst ratings
Erasca Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ERASErasca Inc. Common Stock$13.39▼ 9.95%Market cap $6.25BP/E —$2.11$24.28
- XENEXenon Pharmaceuticals Inc. Common Shares$33.49▼ 2.45%Market cap $6.24BP/E —$33.52$72.66
- BLTEBelite Bio Inc American Depositary Shares$142.78▼ 6.45%Market cap $6.32BP/E —$78.71$200
- DNTHDianthus Therapeutics Inc. Common Stock$72.09▼ 3.27%Market cap $6.15BP/E —$32.22$117.88
- LGNDLigand Pharmaceuticals Incorporated Common Stock$295.54▼ 0.99%Market cap $6.02BP/E 30.38$175.89$326.63
- KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares$78.59▼ 1.69%Market cap $5.97BP/E 77.33$35.2$82.94
- PTCTPTC Therapeutics Inc. Common Stock$59.24▼ 2.87%Market cap $5.91BP/E —$58.8$90.87
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ERAS Erasca Inc. Common Stock | $6.25B | — | $13.39 | ▼ 9.95% | $2.11$24.28 |
| XENE Xenon Pharmaceuticals Inc. Common Shares | $6.24B | — | $33.49 | ▼ 2.45% | $33.52$72.66 |
| BLTE Belite Bio Inc American Depositary Shares | $6.32B | — | $142.78 | ▼ 6.45% | $78.71$200 |
| DNTH Dianthus Therapeutics Inc. Common Stock | $6.15B | — | $72.09 | ▼ 3.27% | $32.22$117.88 |
| LGND Ligand Pharmaceuticals Incorporated Common Stock | $6.02B | 30.38 | $295.54 | ▼ 0.99% | $175.89$326.63 |
| KNSA Kiniksa Pharmaceuticals International plc Class A Ordinary Shares | $5.97B | 77.33 | $78.59 | ▼ 1.69% | $35.2$82.94 |
| PTCT PTC Therapeutics Inc. Common Stock | $5.91B | — | $59.24 | ▼ 2.87% | $58.8$90.87 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Verastem: A Two-For-One Clinical Readout In October And A Commercial LaunchSeekingAlpha · 10/6/2026
- Erasca: Revolution's Approval Just Took Risk Out Of The Fast FollowerSeekingAlpha · 10/5/2026
- Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015Yahoo · 9/22/2026
- Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.Yahoo · 9/16/2026
- Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- Wondering what's happening in today's after-hours session?ChartMill · 9/11/2026
Insider Activity
Insider Actions →- Fuchs Charles S. · August 10, 2026 · Grant1.30M
Institutional Ownership
March 31, 2026
- Total shares held
- 270.89M
- Total value held
- $3.97B
- Institutional holders
- 219
- Unknown24.68M
- Unknown21.26M
- Unknown20.15M
- Unknown16.38M
- Unknown16.16M
- Unknown12.15M
- Unknown11.25M
- Unknown11.24M
- Unknown11.15M
- Unknown10.39M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Erasca Faces Verastem Competition Amid Clinical Updates
Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.
Erasca Faces Verastem Competition Amid Clinical Updates. Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.